147 related articles for article (PubMed ID: 36351931)
1. Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities.
Charland N; Gobeil P; Pillet S; Boulay I; Séguin A; Makarkov A; Heizer G; Bhutada K; Mahmood A; Trépanier S; Hager K; Jiang-Wright J; Atkins J; Saxena P; Cheng MP; Vinh DC; Boutet P; Roman F; Van Der Most R; Ceregido MA; Dionne M; Tellier G; Gauthier JS; Essink B; Libman M; Haffizulla J; Fréchette A; D'Aoust MA; Landry N; Ward BJ
NPJ Vaccines; 2022 Nov; 7(1):142. PubMed ID: 36351931
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial.
Song JY; Choi WS; Heo JY; Lee JS; Jung DS; Kim SW; Park KH; Eom JS; Jeong SJ; Lee J; Kwon KT; Choi HJ; Sohn JW; Kim YK; Noh JY; Kim WJ; Roman F; Ceregido MA; Solmi F; Philippot A; Walls AC; Carter L; Veesler D; King NP; Kim H; Ryu JH; Lee SJ; Park YW; Park HK; Cheong HJ
EClinicalMedicine; 2022 Sep; 51():101569. PubMed ID: 35879941
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19.
Ward BJ; Gobeil P; Séguin A; Atkins J; Boulay I; Charbonneau PY; Couture M; D'Aoust MA; Dhaliwall J; Finkle C; Hager K; Mahmood A; Makarkov A; Cheng MP; Pillet S; Schimke P; St-Martin S; Trépanier S; Landry N
Nat Med; 2021 Jun; 27(6):1071-1078. PubMed ID: 34007070
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine.
Hager KJ; Pérez Marc G; Gobeil P; Diaz RS; Heizer G; Llapur C; Makarkov AI; Vasconcellos E; Pillet S; Riera F; Saxena P; Geller Wolff P; Bhutada K; Wallace G; Aazami H; Jones CE; Polack FP; Ferrara L; Atkins J; Boulay I; Dhaliwall J; Charland N; Couture MMJ; Jiang-Wright J; Landry N; Lapointe S; Lorin A; Mahmood A; Moulton LH; Pahmer E; Parent J; Séguin A; Tran L; Breuer T; Ceregido MA; Koutsoukos M; Roman F; Namba J; D'Aoust MA; Trepanier S; Kimura Y; Ward BJ;
N Engl J Med; 2022 Jun; 386(22):2084-2096. PubMed ID: 35507508
[TBL] [Abstract][Full Text] [Related]
5. Durability and cross-reactivity of immune responses induced by a plant-based virus-like particle vaccine for COVID-19.
Gobeil P; Pillet S; Boulay I; Charland N; Lorin A; Cheng MP; Vinh DC; Boutet P; Van Der Most R; Roman F; Ceregido MA; Landry N; D'Aoust MA; Ward BJ
Nat Commun; 2022 Nov; 13(1):6905. PubMed ID: 36371408
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomised, active-controlled, observer-blinded, phase 3 trial.
Song JY; Choi WS; Heo JY; Kim EJ; Lee JS; Jung DS; Kim SW; Park KH; Eom JS; Jeong SJ; Lee J; Kwon KT; Choi HJ; Sohn JW; Kim YK; Yoo BW; Jang IJ; Capeding MZ; Roman F; Breuer T; Wysocki P; Carter L; Sahastrabuddhe S; Song M; D'Cor N; Kim H; Ryu JH; Lee SJ; Park YW; Cheong HJ;
EClinicalMedicine; 2023 Oct; 64():102140. PubMed ID: 37711219
[TBL] [Abstract][Full Text] [Related]
7. Lack of effects on female fertility or pre- and postnatal development of offspring in rats after exposure to AS03-adjuvanted recombinant plant-derived virus-like particle vaccine candidate for COVID-19.
Dubé C; Paris-Robidas S; Primakova I; Destexhe E; Ward BJ; Landry N; Trépanier S
Reprod Toxicol; 2022 Jan; 107():69-80. PubMed ID: 34838689
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study.
de Bruyn G; Wang J; Purvis A; Ruiz MS; Adhikarla H; Alvi S; Bonaparte MI; Brune D; Bueso A; Canter RM; Ceregido MA; Deshmukh S; Diemert D; Finn A; Forrat R; Fu B; Gallais J; Griffin P; Grillet MH; Haney O; Henderson JA; Koutsoukos M; Launay O; Torres FM; Masotti R; Michael NL; Park J; Rivera-Medina DM; Romanyak N; Rook C; Schuerman L; Sher LD; Tavares-Da-Silva F; Whittington A; Chicz RM; Gurunathan S; Savarino S; Sridhar S;
EClinicalMedicine; 2023 Aug; 62():102109. PubMed ID: 37533419
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial.
Zhang Y; Ma X; Yan G; Wu Y; Chen Y; Zhou Z; Wan N; Su W; Liu FW; Dai MX; Yang M; Li C; Yu X; Zhang L; Wang Z; Zhou TC; You D; Wei J; Zhang Z;
EClinicalMedicine; 2022 Dec; 54():101680. PubMed ID: 36188435
[TBL] [Abstract][Full Text] [Related]
11. A randomised, partially observer blind, multicentre, head-to-head comparison of a two-dose regimen of Baxter and GlaxoSmithKline H1N1 pandemic vaccines, administered 21 days apart.
Nicholson KG; Abrams KR; Batham S; Clark TW; Hoschler K; Lim WS; Medina M; Nguyen-Van-Tam JS; Read RC; Warren FC; Zambon M
Health Technol Assess; 2010 Dec; 14(55):193-334. PubMed ID: 21208550
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study.
Dayan GH; Rouphael N; Walsh SR; Chen A; Grunenberg N; Allen M; Antony J; Bhate AS; Beresnev T; Bonaparte MI; Celle M; Ceregido MA; Corey L; Fu B; Grillet MH; Keshtkar-Jahromi M; Juraska M; Kee JJ; Kaali S; Koutsoukos M; Masotti R; Michael NL; Neuzil KM; Reynales H; Robb ML; Uchiyama A; Sawe F; Schuerman L; Shrestha R; Tong T; Treanor J; Diazgranados CA; Chicz RM; Gurunathan S; Savarino S; Sridhar S;
EClinicalMedicine; 2023 Oct; 64():102168. PubMed ID: 37936652
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan.
Hsieh SM; Liu MC; Chen YH; Lee WS; Hwang SJ; Cheng SH; Ko WC; Hwang KP; Wang NC; Lee YL; Lin YL; Shih SR; Huang CG; Liao CC; Liang JJ; Chang CS; Chen C; Lien CE; Tai IC; Lin TY
Lancet Respir Med; 2021 Dec; 9(12):1396-1406. PubMed ID: 34655522
[TBL] [Abstract][Full Text] [Related]
14. Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial.
Formica N; Mallory R; Albert G; Robinson M; Plested JS; Cho I; Robertson A; Dubovsky F; Glenn GM;
PLoS Med; 2021 Oct; 18(10):e1003769. PubMed ID: 34597298
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
16. Durability and Immunogenicity of Neutralizing Antibodies Response Against Omicron Variants After Three Doses of Subunit SARS-CoV-2 Vaccine MVC-COV1901: An Extension to an Open-Label, Dose-Escalation Phase 1 Study.
Hsieh SM; Chang SC; Cheng HY; Shih SR; Lien CE
Infect Dis Ther; 2022 Aug; 11(4):1493-1504. PubMed ID: 35579840
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults: a phase IV, randomized, open-label, controlled study.
Izurieta P; Kim WJ; Wie SH; Lee J; Lee JS; Dramé M; Vaughn DW; Schuind A
Vaccine; 2015 Jun; 33(24):2800-7. PubMed ID: 25910919
[TBL] [Abstract][Full Text] [Related]
18. Broad neutralization against SARS-CoV-2 variants induced by ancestral and B.1.351 AS03-Adjuvanted recombinant Plant-Derived Virus-Like particle vaccines.
Dubé C; Paris-Robidas S; Andreani G; Gutzeit C; D'Aoust MA; Ward BJ; Trépanier S
Vaccine; 2022 Jun; 40(30):4017-4025. PubMed ID: 35654621
[TBL] [Abstract][Full Text] [Related]
19. Safety and Immunogenicity of a Recombinant Two-Component SARS-CoV-2 Protein Vaccine: Randomized, Double-Blind, Placebo-Controlled Phase I and Phase II Studies.
Wynne C; Balgos A; Li J; Hamilton P; Tirador L; Jaen AM; Mo C; Yue Z; Ma Y; Wang Q; Wen R; Yao Z; Yu J; Yao W; Zhang J; Zheng H; Hong K; Zhu F; Liu Y
Infect Dis Ther; 2024 Jan; 13(1):57-78. PubMed ID: 38103161
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months.
Carmona A; Omeñaca F; Tejedor JC; Merino JM; Vaman T; Dieussaert I; Gillard P; Arístegui J
Vaccine; 2010 Aug; 28(36):5837-44. PubMed ID: 20600478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
